Mizuho said the label for Gilead’s (GILD) Yeztugo, or lenacapavir, looks clean following FDA approval of the injectable HIV-1 capsid inhibitor. The firm added that lenacapavir potentially opens the market, over time, to additional populations beyond the currently estimated 1.2M-2.25M eligible consumers. The $28.2K per year in wholesale acquisition cost for continuing therapy is roughly in-line with existing branded options, according to Mizuho. The firm reiterated an Outperform rating and $117 price target on shares of Gilead.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating
- Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option
- FDA approves Gilead’s Yeztugo for pre-exposure HIV prophylaxis
- Gilead receives FDA approval for HIV prevention injection
- Gilead Sciences: Strong HIV Market Position and Diversified Growth Strategy Justify Buy Rating